SANUWAVE Health Inc
OTC:SNWV
SANUWAVE Health Inc
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. The company is headquartered in Suwanee, Georgia and currently employs 43 full-time employees. The company went IPO on 2008-11-07. The firm's is focused on regenerative medicine utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The firm's lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. The company intends to apply its Pulsed Acoustic Cellular Expression (PACE) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions.
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. The company is headquartered in Suwanee, Georgia and currently employs 43 full-time employees. The company went IPO on 2008-11-07. The firm's is focused on regenerative medicine utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. The firm's lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. The company intends to apply its Pulsed Acoustic Cellular Expression (PACE) technology in wound healing, orthopedic, plastic/cosmetic and cardiac conditions.
Record Revenue: Q3 revenue is expected between $11.4 million and $11.6 million, a company record and up 12% to 14% from Q2, but below previous guidance.
Guidance Lowered: Annual revenue guidance was reduced to $44 million to $46 million, down from $48 million to $50 million, implying about 40% growth at the midpoint.
Market Disruption: Uncertainty around reimbursement changes for skin substitute and allograft products led to a slower start in Q3, though business picked up markedly in September.
Sales Momentum: A record 155 systems were placed in Q3, with September being the best month ever for revenue, system sales, and applicators.
Pipeline & Outlook: Management reports a robust sales pipeline and continued traction, particularly after industry events reduced uncertainty, but cautions that deal closures are taking longer than anticipated.
